Lucid Diagnostics Inc.
LUCD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.01 | 0.05 | -0.10 |
| FCF Yield | -9,266.72% | -12,160.26% | -21.44% | -25.64% |
| EV / EBITDA | -26.19 | -4.22 | -4.08 | -3.26 |
| Quality | ||||
| ROIC | -25,007.73% | -41.77% | -46.44% | -60.27% |
| Gross Margin | -53.48% | -87.32% | -79.20% | -43.69% |
| Cash Conversion Ratio | 1.05 | 2.38 | 0.46 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 831.96% | 76.50% | 87.41% | 125.90% |
| Free Cash Flow Growth | 15.37% | -122,950.35% | 3.75% | 8.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.85 | -0.38 | 0.10 | 0.12 |
| Interest Coverage | -1,897.33 | -1,387.44 | -1,767.86 | -11,694.00 |
| Efficiency | ||||
| Inventory Turnover | 1.82 | 3.20 | 6.29 | 2.59 |
| Cash Conversion Cycle | 36.33 | -13.39 | -7.31 | -22.87 |